Epigenetic Biomarker

A cancer biomarker is a biological marker which indicates the presence of cancer in the body. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers are used for diagnosis, prognosis, and epidemiology of cancer.

Because they are expressed against a person's genetic background and environmental exposure, and epigenetic events occur early in cancer development, Epigenetic biomarkers are more advantageous over other types of biomarkers.

Epigenetic biomarkers potentially have numerous clinical applications in cancer intervention and treatment and significant implications for public health.

Types of epigenetic biomarkers:

  • DNA methylation, circulating or noncirculating
  • MicroRNA and other noncoding RNA
  • Protein markers

For e.g., DNA methylation is one of the major epigenetic mechanisms and it is a genetic feature better reflecting disease development and, consequently, has the potential to become a more conclusive biomarker for detection and diagnosis of different diseases.

    Related Conference of Epigenetic Biomarker

    March 10-11, 2025

    3rd World Congress on Oral Cancer

    Paris, France
    March 24-25, 2025

    25th World Congress on Cancer and Diagnostics

    London, UK
    March 24-25, 2025

    10th World Conference on Breast and Cervical Cancer

    Paris, France
    April 07-08, 2025

    15th World Congress on Breast Cancer

    Vancouver, Canada
    June 16-17, 2025

    26th World Congress on Cancer Summit

    Amsterdam, Netherlands
    July 14-15, 2025

    5th World Congress on Breast Cancer

    Berlin, Germany
    October 20-21, 2025

    21st International Conference on Cancer Research

    Barcelona, Spain

    Epigenetic Biomarker Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in